Stephens Begins Coverage on Pyxis Oncology (NASDAQ:PYXS)

Equities researchers at Stephens started coverage on shares of Pyxis Oncology (NASDAQ:PYXS) in a research report issued to clients and investors on Friday, MarketBeat.com reports. The firm set an “overweight” rating and a $13.00 price target on the stock. Stephens’ price target would indicate a potential upside of 229.95% from the company’s previous close.

PYXS has been the topic of several other reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research note on Thursday, September 19th. Stifel Nicolaus began coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They issued a “buy” rating and a $10.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research note on Friday, August 16th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $9.57.

Pyxis Oncology Stock Performance

PYXS stock opened at $3.94 on Friday. The company’s 50 day moving average price is $3.58 and its 200 day moving average price is $3.66. Pyxis Oncology has a fifty-two week low of $1.35 and a fifty-two week high of $6.85. The firm has a market capitalization of $234.13 million, a price-to-earnings ratio of -3.18 and a beta of 1.27.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. Equities analysts forecast that Pyxis Oncology will post -1.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Pyxis Oncology

A number of hedge funds have recently modified their holdings of PYXS. StemPoint Capital LP purchased a new position in shares of Pyxis Oncology during the first quarter worth approximately $7,643,000. Ikarian Capital LLC purchased a new position in shares of Pyxis Oncology during the first quarter worth approximately $7,082,000. Blue Owl Capital Holdings LP purchased a new position in shares of Pyxis Oncology during the second quarter worth approximately $3,462,000. Millennium Management LLC grew its position in shares of Pyxis Oncology by 125.3% during the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after acquiring an additional 743,499 shares during the last quarter. Finally, abrdn plc lifted its holdings in shares of Pyxis Oncology by 28.9% during the third quarter. abrdn plc now owns 913,045 shares of the company’s stock worth $3,351,000 after purchasing an additional 204,742 shares during the period. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.